Intellia Therapeutics rises on narrower Q1 loss
** Shares of gene-editing firm Intellia Therapeutics NTLA.O rise 3.4% to $7.54 ** NTLA reports Q1 net loss of $1.10 per share, narrower than the net loss of $1.12 a year ago ** Posts Q1 collaboration revenue of $16.63 million, compared with $28.9 million a year ago ** Co says it has cash and cash equivalents of $707.1 million as of March 31, with runway expected into H1 2027 ** Including session's moves, stock down 35.4% YTD (Reporting by Siddhi Mahatole) ((siddhi.mahatole@thomsonreuters.com))
Recent news on INTELLIA THERAPEUTICS
See all newsU.S. STOCKS ON THE MOVE-Best Buy, Peloton, Apple
U.S. STOCKS ON THE MOVE-Qualcomm, Eaton, Howmet Aerospace
U.S. STOCKS ON THE MOVE-Sigma Lithium, Shake Shack, Novartis
Intellia rises after FDA grants fast-track status to its treatment for rare disease
Brief: Intellia Therapeutics Announces FDA Acceptance Of Biologics License Application With Priority Review For Lonvoguran Ziclumeran (Lonvo-Z) For Hereditary Angioedema (Hae)